• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

A new molecule to fight type 2 diabetes and non-alcoholic fatty liver disease

Bioengineer by Bioengineer
April 10, 2019
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Diabetes: research on active drugs orally administrated

IMAGE

Credit: UNIVERSITY OF BARCELONA

A new molecule -EPB-53-, could help fight type 2 diabetes and the non-alcoholic fatty liver disease, according to a new study led by the team of Manuel Vázquez-Carrera, from the Faculty of Pharmacy and Food Sciences and the Institute of Biomedicine of the University of Barcelona (IBUB), and the Diabetes and Associated Metabolic Diseases Networking Biomedical Research Centre (CIBERDEM).

Other participants in the study, published in the journal British Journal of Pharmacology, are the members of the teams led by the researchers Francesc Villarroya, from the Faculty of Biology and the Institute of Biomedicine of the University of Barcelona (IBUB) and member of the Physiopathology of Obesity and Nutrition Networking Biomedical Research Centre (CIBERobn) and the Research Institute Sant Joan de Déu; and Santiago Vázquez, from the Pharmaceutical Chemistry Unit of the Faculty of Pharmacy and Food Sciences of the UB and IBUB.

Diabetes: research on active drugs orally administrated

The FGF21 hormone -the fibroblast growth factor 21- is an endocrine factor with a determining role in the energetic metabolism as an anti-diabetes and anti-obesity agent. This hormone, which mainly synthetises the liver, is regarded as a potential therapeutic target to treat type 2 diabetes and the non-alcoholic fatty liver disease, which usually occur due obesity and insulin resistance. However, the FGF21 analogue compounds that showed pharmaceutical activity in animal models require subcutaneous injection, and can generate adverse effects (loss of bone mass, increase of heart rate and arterial pressure, etc.).

According to the new pre-clinical study, levels of FGF21 in the liver and plasma can increase through oral administration of the EPB-53 molecule. “This effect is possible because EPB-53 is a molecule that activates HRI (eIF2α kinase regulated by hemo group), a kinase that can boost a factor of transcription involved in the increae of FGF21, which reduces glucose tolerance and hepatic steatosis in mice which are fed with a fat-rich diet”, notes the researcher Manuel Vázquez-Carrera, from the Department of Pharmacology, Toxicology and Therapeutical Chemistry of the UB.

A growing problem on global health

The conclusions of the study prove the use of FGF21 inducer compounds could lead to new therapeutic strategies to treat type 2 diabetes and the non-alcoholic fatty liver disease, similarly to what analogue compounds do subcutaneously.

“In addition, we hope to see in future studies that these would not cause adverse effects that have been described in some FGF21 analogues. Therefore, we are working on the development of new HRI activators with better pharmacokinetic characteristics for the treatment of type 2 diabetes such as non-alcoholic steatohepatitis”, notes Vázquez-Carrera.

The incidence of type 2 mellitus diabetes has grown among the population over the last years and the available drugs cannot control the progress of the disease in all patients. Also, the non-alcoholic fatty liver disease affects one out of four people and the worst cases -non-alcoholic steatohepatitis- do not have any specific approved drug. Finding new drugs for oral administration is, thus, one of the challenges in biomedicine to improve health care for millions of people worldwide, who are affected by these metabolic diseases.

###

Media Contact
Rosa Martínez
[email protected]

Original Source

https://www.ncbi.nlm.nih.gov/pubmed/30927369

Related Journal Article

http://dx.doi.org/10.1111/bph.14678

Tags: DiabetesDiet/Body WeightDisease in the Developing WorldEndocrinologyInternal MedicineLiverMedicine/HealthMetabolism/Metabolic DiseasesNutrition/NutrientsPharmaceutical Science
Share13Tweet8Share2ShareShareShare2

Related Posts

GBA1 Variants’ Impact on Parkinson’s: In Silico Analysis

GBA1 Variants’ Impact on Parkinson’s: In Silico Analysis

August 2, 2025
Deep Learning Advances MRI Diagnosis of Brucella

Deep Learning Advances MRI Diagnosis of Brucella

August 2, 2025

Predicting Lung Infections After Brain Hemorrhage

August 2, 2025

Impact of Morphology and Location on Aneurysms

August 2, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    41 shares
    Share 16 Tweet 10
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

AI Virtual Lab Engineers New SARS-CoV-2 Nanobodies

GBA1 Variants’ Impact on Parkinson’s: In Silico Analysis

Rotterdam Oncology: Premier Head & Neck Biobank

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.